Loading clinical trials...
Loading clinical trials...
A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection
Conditions
Interventions
DCV
SOF
+1 more
Locations
19
United States
Keck Medical Center Of USC
Los Angeles, California, United States
University Of California, San Francisco
San Francisco, California, United States
Gastrointestinal Specialists of Georgia, PC
Marietta, Georgia, United States
Ruth Rothstein Core Center
Chicago, Illinois, United States
Digestive Disease Associates, PA
Catonsville, Maryland, United States
Northeast Clinical Research Center
Bethlehem, Pennsylvania, United States
Start Date
March 15, 2016
Primary Completion Date
March 2, 2017
Completion Date
May 26, 2017
Last Updated
May 8, 2018
NCT06953479
NCT04162938
NCT03135886
NCT05968573
NCT01644903
NCT05042544
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions